San Diego-dependent Viking Therapeutics marked by itself as a significant competitor in the weight loss drug current market in February after revealing promising knowledge from the mid-stage trial of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when given as being a weekly injection As well as in March